DK1084569T3 - Androgener i kombination med gestagener til udligning af et testosteronunderskud med beskyttelse af prostata - Google Patents

Androgener i kombination med gestagener til udligning af et testosteronunderskud med beskyttelse af prostata

Info

Publication number
DK1084569T3
DK1084569T3 DK99938132T DK99938132T DK1084569T3 DK 1084569 T3 DK1084569 T3 DK 1084569T3 DK 99938132 T DK99938132 T DK 99938132T DK 99938132 T DK99938132 T DK 99938132T DK 1084569 T3 DK1084569 T3 DK 1084569T3
Authority
DK
Denmark
Prior art keywords
combination
testosterone
progestogens
androgens
offset
Prior art date
Application number
DK99938132T
Other languages
English (en)
Inventor
Doris Huebler
Michael Oettel
Lothar Sobek
Walter Elger
Abdul-Abbas Al-Mudhaffar
Original Assignee
Jenapharm Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7870308&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1084569(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Jenapharm Gmbh filed Critical Jenapharm Gmbh
Application granted granted Critical
Publication of DK1084569T3 publication Critical patent/DK1084569T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/565—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids not substituted in position 17 beta by a carbon atom, e.g. estrane, estradiol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • A61K31/585—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin containing lactone rings, e.g. oxandrolone, bufalin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/24—Drugs for disorders of the endocrine system of the sex hormones
    • A61P5/26—Androgens

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Endocrinology (AREA)
  • Diabetes (AREA)
  • Urology & Nephrology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Steroid Compounds (AREA)
DK99938132T 1998-06-09 1999-06-07 Androgener i kombination med gestagener til udligning af et testosteronunderskud med beskyttelse af prostata DK1084569T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19825591A DE19825591A1 (de) 1998-06-09 1998-06-09 Pharmazeutische Kombinationen zum Ausgleich eines Testosteron-Defizits beim Mann mit gleichzeitigem Schutz der Prostata
PCT/DE1999/001652 WO1999065228A2 (de) 1998-06-09 1999-06-07 Pharmazeutische kombinationen zum ausgleich eines testosteron-defizits mit schutz der prostata

Publications (1)

Publication Number Publication Date
DK1084569T3 true DK1084569T3 (da) 2003-06-30

Family

ID=7870308

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99938132T DK1084569T3 (da) 1998-06-09 1999-06-07 Androgener i kombination med gestagener til udligning af et testosteronunderskud med beskyttelse af prostata

Country Status (11)

Country Link
US (1) US20070078091A1 (da)
EP (1) EP1084569B1 (da)
JP (1) JP3645489B2 (da)
AT (1) ATE233976T1 (da)
AU (1) AU5277599A (da)
CL (1) CL2004000628A1 (da)
DE (2) DE19825591A1 (da)
DK (1) DK1084569T3 (da)
ES (1) ES2194495T3 (da)
PT (1) PT1084569E (da)
WO (1) WO1999065228A2 (da)

Families Citing this family (38)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2003534375A (ja) * 2000-05-26 2003-11-18 フィッチ，ハリー 選択性抗エストロゲン薬を用いた男性におけるアンドロゲン欠乏症の治療法
PT1210951E (pt) * 2000-11-30 2005-04-29 Pfizer Prod Inc Composicao que contem agonistas/antagonistas de estrogeneo e testosterona para tartamento de um declinio do nivel da hormona testosterona
US7019012B2 (en) * 2000-12-20 2006-03-28 Boehringer Ingelheim International Pharma Gmbh & Co. Kg Quinazoline derivatives and pharmaceutical compositions containing them
DE10221018A1 (de) * 2002-05-11 2003-11-27 Boehringer Ingelheim Pharma Verwendung von Hemmern der EGFR-vermittelten Signaltransduktion zur Behandlung von gutartiger Prostatahyperplasie (BPH)/Prostatahypertrophie
WO2005066195A1 (de) * 2004-01-02 2005-07-21 Pharmacon Forschung Und Beratung Gmbh Verfahren zur herstellung von 1,2-ungesättigten azasteroiden
US7138389B2 (en) * 2004-02-09 2006-11-21 University Of Washington Oral androgen therapy using modulators of testosterone bioavailability
EP1734963A4 (en) * 2004-04-02 2008-06-18 Merck & Co Inc METHOD FOR TREATING PEOPLE WITH METABOLIC AND ANTHROPOMETRIC DISORDER
CN101146535A (zh) * 2005-03-25 2008-03-19 默克公司 用睾酮补充剂和5α-还原酶抑制剂治疗男性病人的方法
EP3173084B1 (en) 2005-11-11 2019-10-23 Boehringer Ingelheim International GmbH Quinazoline derivatives for the treatment of cancer diseases
EP1968705A1 (en) * 2005-12-21 2008-09-17 Pfizer Products Incorporated Pharmaceutical combination of a pde-5 inhibitor and a 5-alpha reductase inhibitor
US20110092470A1 (en) * 2006-03-21 2011-04-21 Alan Meehan Method of treating men with erectile dysfunction
PT2068880E (pt) 2006-09-18 2012-07-12 Boehringer Ingelheim Int Método para tratamento do cancro apresentando mutações no egfr
EP2363397A4 (en) * 2008-11-07 2012-07-11 Dainippon Sumitomo Pharma Co NEW THERAPEUTIC AGENT USEFUL FOR SYMPTOM OF LOWER URINARY TRACT
EP2266568A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of LHRH antagonists in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
EP2266567A1 (en) 2009-05-26 2010-12-29 Æterna Zentaris GmbH Use of cetrorelix in combination with PDE V inhibitors for the treatment of sex hormone dependent disorders
PT2451445T (pt) 2009-07-06 2019-07-10 Boehringer Ingelheim Int Processo para secagem de bibw2992, dos seus sais e de formulações farmacêuticas sólidas compreendendo este ingrediente ativo
JP5847730B2 (ja) * 2009-12-31 2016-01-27 ディッフェレンシャル ドラッグ ディベロップメント アソシエイツ，エルエルシー ステロールによる親油性薬剤の溶解性、安定性、吸収性、代謝性、及び薬物動態プロファイルの調節
US20130303495A1 (en) * 2009-12-31 2013-11-14 Sov Therapeutics Emulsion formulations
BR112014012444B1 (pt) 2011-11-23 2021-12-14 Therapeuticsmd, Inc Composição farmacêutica compreendendo estradiol solubilizado, progesterona e um agente de solubilização, bem como usos desta para tratar um sintoma relacionado à menopausa em uma mulher
US9301920B2 (en) 2012-06-18 2016-04-05 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US20130338122A1 (en) 2012-06-18 2013-12-19 Therapeuticsmd, Inc. Transdermal hormone replacement therapies
US20150196640A1 (en) 2012-06-18 2015-07-16 Therapeuticsmd, Inc. Progesterone formulations having a desirable pk profile
US10806697B2 (en) 2012-12-21 2020-10-20 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10806740B2 (en) 2012-06-18 2020-10-20 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US11266661B2 (en) 2012-12-21 2022-03-08 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10537581B2 (en) 2012-12-21 2020-01-21 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10568891B2 (en) 2012-12-21 2020-02-25 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US9180091B2 (en) 2012-12-21 2015-11-10 Therapeuticsmd, Inc. Soluble estradiol capsule for vaginal insertion
US11246875B2 (en) 2012-12-21 2022-02-15 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
US10471072B2 (en) 2012-12-21 2019-11-12 Therapeuticsmd, Inc. Vaginal inserted estradiol pharmaceutical compositions and methods
NZ631833A (en) 2013-03-15 2017-06-30 Differential Drug Dev Ass Llc Emulsion formulations
US9242965B2 (en) 2013-12-31 2016-01-26 Boehringer Ingelheim International Gmbh Process for the manufacture of (E)-4-N,N-dialkylamino crotonic acid in HX salt form and use thereof for synthesis of EGFR tyrosine kinase inhibitors
US9744177B2 (en) 2014-03-10 2017-08-29 Endorecherche, Inc. Treatment of male androgen deficiency symptoms or diseases with sex steroid precursor combined with SERM
AU2015264003A1 (en) 2014-05-22 2016-11-17 Therapeuticsmd, Inc. Natural combination hormone replacement formulations and therapies
US10328087B2 (en) 2015-07-23 2019-06-25 Therapeuticsmd, Inc. Formulations for solubilizing hormones
WO2017173044A1 (en) 2016-04-01 2017-10-05 Therapeuticsmd Inc. Steroid hormone compositions in medium chain oils
BR112018070199A2 (pt) 2016-04-01 2019-01-29 Therapeuticsmd Inc composição farmacêutica de hormônio esteroide
BE1028115B1 (fr) * 2020-03-02 2021-09-27 Georges Debled Composition pour le traitement des cancers

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3423507A (en) * 1966-02-25 1969-01-21 Schering Corp Method of treating benign prostratic hypertrophy
DE2817157A1 (de) * 1978-04-17 1979-10-25 Schering Ag Verwendung von antioestrogenen und antigonadotrop wirkenden antiandrogenen zur prophylaxe und therapie der prostatahyperplasie
DE3121152A1 (de) * 1981-05-22 1982-12-09 Schering Ag, 1000 Berlin Und 4619 Bergkamen "verwendung der kombination eines aromatase-hemmers mit einem antiandrogen zur prophylaxe und therapie der prostatahyperplasie"
US4704282A (en) * 1984-06-29 1987-11-03 Alza Corporation Transdermal therapeutic system having improved delivery characteristics
GB8506027D0 (en) * 1985-03-08 1985-04-11 Efamol Ltd Pharmaceutical & dietary compositions
US5059603A (en) * 1989-06-12 1991-10-22 Centuries Laboratories, Inc. Method and composition for treating impotence
IN171596B (da) * 1989-06-27 1992-11-21 Cohen Michael
ES2222633T3 (es) * 1989-07-07 2005-02-01 Endorecherche Inc. Terapia combinada para la profilaxis y/o el tratamiento de la hiperplasia prostatica benigna.
DE4312034A1 (de) * 1993-04-13 1994-10-20 Hesch Rolf Dieter Prof Dr Med Neuartige Androgene und Anabolika
DE4318371A1 (de) * 1993-05-28 1994-12-01 Schering Ag Mittel, enthaltend eine Verbindung mit antiandrogener sowie eine Verbindung mit kompetitiver, progesteronantagonistischer Wirkung
ES2176218T3 (es) * 1993-11-19 2002-12-01 Jenapharm Gmbh Agente carcinostatico para terapia hormonal que contiene dienogesto como componente activo.
US5609617A (en) * 1995-02-21 1997-03-11 C. Norman Shealy Method for enhancement of dehydroepiandrosterone
US5599822A (en) * 1995-06-06 1997-02-04 Eli Lilly And Company Methods for minimizing bone loss
AUPN814496A0 (en) * 1996-02-19 1996-03-14 Monash University Dermal penetration enhancer
CA2323089A1 (en) * 1998-03-11 1999-09-16 Endorecherche, Inc. Inhibitors of type 5 and type 3 17.beta.-hydroxysteroid dehydrogenase and methods for their use

Also Published As

Publication number Publication date
AU5277599A (en) 1999-12-30
US20070078091A1 (en) 2007-04-05
ES2194495T3 (es) 2003-11-16
DE19825591A1 (de) 1999-12-23
DE59904462D1 (de) 2003-04-10
EP1084569A2 (de) 2001-03-21
EP1084569B1 (de) 2003-03-05
CL2004000628A1 (es) 2005-01-07
WO1999065228A3 (de) 2000-09-14
PT1084569E (pt) 2003-07-31
WO1999065228A2 (de) 1999-12-16
JP2002518294A (ja) 2002-06-25
JP3645489B2 (ja) 2005-05-11
ATE233976T1 (de) 2003-03-15

Similar Documents

Publication Publication Date Title
DK1084569T3 (da) Androgener i kombination med gestagener til udligning af et testosteronunderskud med beskyttelse af prostata
GEP20074122B (en) Treating benign prostate hyperplasia with selective androgen receptor modulators
NO308037B1 (no) 16-substituerte-4-aza-androstan 5<alfa>-reduktase-isoenzym 1- inhibitorer og farmasøytisk preparat
MXPA00008738A (es) 20-ceto-1 1b-arilesteroides y sus derivados teniendo propiedades agonistas o antagonistas hormonales.
MY106484A (en) Combination therapy for phophylaxis and/or treatment of benign prostatic hyperplasia.
HUP0000261A2 (hu) Módszer prosztatatúltengés és prosztatarák kezelésére
MXPA02005007A (es) Uso de un antagonista h1 y un esteroide inocuo para tratar condiciones oculares.
AU1316000A (en) Compositions and methods for treating benign prostatic hyperplasia using tocotrienols
HK1071697A1 (en) Inhibition of the growth factor dependency of tumor cells
DE60136618D1 (de) Verwendung von 13-hode als regulator der vaskulären biokompatibilität und als inhibitor der zellulären hyperplasie
WO2003024405A3 (en) Methods and compositions for inhibiting the proliferation of prostate cancer cells
RS92304A (en) Pharmaceutical combination for the treatment of benign prostatic hyperplasia or for long-term preservation of acute urinary retention
DE69417925T2 (de) 7-substituierte-4-aza-steroid-derivate als 5-alpha-reductase-hemmer
DK0885005T3 (da) Anvendelse af dehydroepiandrosteron og aromatasehæmmere til fremstilling af et lægemiddel til behandling af en relativ og absolut androgenmangel hos mænd
SI1135403T1 (en) 17beta-acyl-17alpha-propynyl-11beta-arylsteroids and their derivatives having agonist or antagonist hormonal properties
IL174545A (en) Use of a two-component system for the preparation of a hair growth inhibiting composition
PL344413A1 (en) 17β-AMINO AND HYDROXYLAMINO-11β-ARYLSTEROIDS AND THEIR DERIVATIVES HAVING AGONIST OR ANTAGONIST HORMONAL PROPERTIES
WO2009053857A3 (en) Management and treatment of benign prostatic hyperplasia
AR026901A1 (es) Peptidos con n-alquilacion que tienen actividad antiangiogenica
EA199900914A1 (ru) Лечение или профилактика рака простаты и доброкачественной гиперплазии простаты селективными модуляторами рецепторов эстрогена
DK0880540T3 (da) 17-Beta-cyclopropyl(amino/oxy)-4-azasteroider som aktive inhibitorer af testosteron 5-alfa-reduktase og C17-20-lyase
MXPA03001986A (es) Composiciones antitromboticas.
MXPA02008014A (es) Composiciones inhibidoras de tumores de 1-nitroacridina.
ECSP982362A (es) Compuestos de quinolina y quinazolina utiles en terapia
SI1501517T1 (sl) Farmacevtska kombinacija za zdravljenje benigne hiperplazije prostate ali za dolgotrajno preprečevanje akutne retencije urina